Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype
- PMID: 14583457
Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype
Abstract
A database has been created to collect information on families carrying a germ-line mutation in the TP53 gene and on families affected with Li-Fraumeni syndromes [Li-Fraumeni syndrome (LFS) and Li-Fraumeni-like syndrome (LFL)]. Data from the published literature have been included. The database is available online at http://www.iarc.fr/p53, as part of the IARC TP53 Database. The analysis of the 265 families/individuals that have been included thus far has revealed several new findings. In classical LFS families with a germ-line TP53 mutation (83 families), the mean age of onset of breast cancer was significantly lower than in LFS families (16 families) without a TP53 mutation (34.6 versus 42.5 years; P = 0.0035). In individuals with a TP53 mutation, a correlation between the genotype and phenotype was found. Brain tumors were associated with missense TP53 mutations located in the DNA-binding loop that contact the minor groove of DNA (P = 0.01), whereas adrenal gland carcinomas were associated with missense mutations located in the loops opposing the protein-DNA contact surface (P = 0.003). Finally, mutations likely to result in a null phenotype (absence of the protein or loss of function) were associated with earlier onset brain tumors (P = 0.004). These observations have clinical implications for genetic testing and tumor surveillance in LFS/LFL families.
Similar articles
-
TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.J Med Genet. 2010 Jun;47(6):421-8. doi: 10.1136/jmg.2009.073429. J Med Genet. 2010. PMID: 20522432
-
Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.Oncogene. 1998 Sep 3;17(9):1061-8. doi: 10.1038/sj.onc.1202033. Oncogene. 1998. PMID: 9764816
-
Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families.Cancer Res. 1997 Aug 1;57(15):3245-52. Cancer Res. 1997. PMID: 9242456
-
Germline TP53 mutations and Li-Fraumeni syndrome.Hum Mutat. 2003 Mar;21(3):313-20. doi: 10.1002/humu.10185. Hum Mutat. 2003. PMID: 12619118 Review.
-
[Li-Fraumeni syndrome].Bull Cancer. 1997 Jul;84(7):735-40. Bull Cancer. 1997. PMID: 9339200 Review. French.
Cited by
-
Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.J Clin Oncol. 2015 Feb 20;33(6):602-9. doi: 10.1200/JCO.2013.52.6863. Epub 2015 Jan 12. J Clin Oncol. 2015. PMID: 25584008 Free PMC article.
-
Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.Perm J. 2015 Spring;19(2):48-79. doi: 10.7812/TPP/14-241. Perm J. 2015. PMID: 25902343 Free PMC article. Review.
-
Molecular pathology of adrenal cortical tumors: separating adenomas from carcinomas.Endocr Pathol. 2006 Winter;17(4):355-63. doi: 10.1007/s12022-006-0007-z. Endocr Pathol. 2006. PMID: 17525484 Review.
-
p53 downregulates its activating vaccinia-related kinase 1, forming a new autoregulatory loop.Mol Cell Biol. 2006 Jul;26(13):4782-93. doi: 10.1128/MCB.00069-06. Mol Cell Biol. 2006. PMID: 16782868 Free PMC article.
-
Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.Mol Cancer Res. 2010 May;8(5):701-16. doi: 10.1158/1541-7786.MCR-09-0442. Epub 2010 Apr 20. Mol Cancer Res. 2010. PMID: 20407015 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous